X0206 3 2021-10-07 0 0001782223 Pyxis Oncology, Inc. PYXS 0001126556 FLAVIN JOHN L C/O PYXIS ONCOLOGY, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 true Common Stock 169222 D Series B Convertible Preferred Stock Common Stock 2388 D Stock Option (Right to buy) 8.71 2031-08-18 Common Stock 15725 D Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date. Each 6.359 shares of Series B Convertible Preferred Stock are currently convertible into one share of Common Stock at the option of the holder, for no additional consideration, and will convert automatically upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). These shares have no expiration date. These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date. Exhibit List: Exhibit 24 - Power of Attorney /s/ Pamela Connealy, Attorney-in-Fact for John Flavin 2021-10-07